Investment Case Summary
- Bellberry approval unlocks a national multi-site rollout for HARNESS-1, cutting the biggest source of trial delay risk.
- Chris O'Brien Lifehouse and Austin Health add the patient throughput needed to move Phase 1a/b enrolment at pace.
- The real valuation lever remains a partnership or licensing deal on RC220, not the ethics approvals themselves.
Bellberry tick opens Chris O’Brien Lifehouse and Austin Health, tightening the path to Phase 1b
Racura Oncology (ASX:RAC) has cleared a procedural hurdle that matters more than it sounds. The Bellberry Human Research Ethics Committee has approved the HARNESS-1 lung cancer trial, allowing additional Australian sites to come online beyond the lead site at Monash Health.
In practice, that means Chris O’Brien Lifehouse in Sydney and Austin Health in Melbourne can now progress to governance and start-up. Both are marquee cancer centres, and both add the kind of patient throughput a Phase 1a/b oncology trial actually needs to run on schedule.
HARNESS-1 is testing Racura’s lead asset RC220, a proprietary formulation of (E,E)-bisantrene, in combination with AstraZeneca’s Tagrisso in EGFR-mutant non-small cell lung cancer. This is the second of Racura’s three RC220 programs, sitting alongside the Phase 3 AML program and a solid tumour combination study with doxorubicin.
For a clinical-stage biotech, ethics approvals are the boring milestones that quietly decide whether a trial reads out on time or slips a year. This one keeps HARNESS-1 on the right side of that equation.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
Why Bellberry approval is the real bottleneck, not the science
The scientific case for HARNESS-1 was already set when Monash Health signed on late last year. What was missing was a mechanism to activate private hospitals and public hospitals outside Victoria without running a separate ethics review at each one.
Bellberry is a national multi-site ethics committee, and its approval effectively turns a slow site-by-site process into a much faster rollout. Chris O’Brien Lifehouse and Austin Health are the first two sites through the door, and management has flagged further sites in the coming months.
For investors, the takeaway is straightforward. Enrolment risk is the single biggest reason small biotech trials slip. Broadening the site network before dose escalation gets deep is exactly the sequencing you want to see.
The RC220 story is really a MYC story
RC220 works by binding G4-DNA and RNA structures, which in turn silences MYC, one of the most heavily studied cancer growth regulators in oncology. MYC has been called undruggable for decades, so any credible clinical readout that ties MYC suppression to patient benefit is commercially meaningful.
The HARNESS-1 combination angle is also worth noting. Tagrisso is the standard of care in EGFR-mutant NSCLC, but resistance eventually develops in most patients. Layering RC220 onto maintenance osimertinib is a logical bet on delaying or reversing that resistance.
The trial is designed as a dose escalation of 12 to 40 patients, followed by a 40-patient randomised Phase 1b expansion. Endpoints include progression-free survival, overall survival and ctDNA dynamics, which is a richer readout package than the typical Phase 1 setup.
What this approval does and does not tell you
We think it is important to be honest about what today’s announcement is. It is a governance milestone, not a data event. Nobody has been dosed at either of the new sites yet, and the meaningful safety and PK data from HARNESS-1 is still some way off.
The skeptical read is that Racura still needs to convert three concurrent clinical programs into a single commercial story, and the market has historically been unforgiving of biotechs with fragmented pipelines. Partnership or licensing progress on RC220 is what would really move the valuation.
That said, ethics approvals compound. Each new site opened is a small reduction in trial risk, and Racura is quietly de-risking HARNESS-1 while attention sits on the Phase 3 AML program.
The Investors Takeaway for Racura Oncology
With Bellberry approval in hand and two top-tier centres coming online, the question for Racura shifts from can we open sites to how fast can we recruit patients. Investors should be watching for first patient dosed announcements and, further out, initial safety and PK signals from the dose-escalation cohort.
The bigger prize sits behind HARNESS-1, in the form of partnership or licensing conversations around RC220. A clean early readout in EGFR-mutant NSCLC on top of the Phase 3 AML program is the kind of data package that makes those conversations easier to price.
Investors can find more in-depth coverage of ASX-listed biotech names at stocksdownunder.
